|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2007-6-22
|
|
pubmed:abstractText |
Regardless the mobilization procedure used there is a great variability from patient to patient in the yield of CD34 collections for autologous transplantation. We analyzed retrospectively our non-Hodgkin's lymphoma survey of 60 patients harvested with G-CSF alone after a unique first line chemotherapy; 67% of patients harvested a sufficient number of CD34+ cells during the first attempt of mobilization. The charachteristics of leukaphereses procedures were the same for all the patients. Sex, age, months from the end of chemo- or radio-therapy did not have a significance in influencing mobilization capability, while requirement of G-CSF during chemotherapy was statistically different from failures to successes: 16/20 (80%) of patients failing to reach the target of 2x10(6)/kg CD34+ cells had required G-CSF support during previous chemotherapy versus 18/40 (45%) in the successful group (p 0,005). Our observation supports the hypotesis that individual biological charachteristics of each patient are the most important factors in affecting mobilization capability, deserving further investigation: mobilization schedules tailored on a given patient would minimize the rate of failures, avoiding a second attempt of collection that implies additional economic expenses and negative consequences on the maintenance of dose intensity.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1125-5552
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
6
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
11-6
|
|
pubmed:meshHeading |
pubmed-meshheading:17582943-Adolescent,
pubmed-meshheading:17582943-Adult,
pubmed-meshheading:17582943-Antigens, CD34,
pubmed-meshheading:17582943-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17582943-Cyclophosphamide,
pubmed-meshheading:17582943-Cytarabine,
pubmed-meshheading:17582943-Dose-Response Relationship, Drug,
pubmed-meshheading:17582943-Doxorubicin,
pubmed-meshheading:17582943-Female,
pubmed-meshheading:17582943-Fluorouracil,
pubmed-meshheading:17582943-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:17582943-Hematopoietic Stem Cell Mobilization,
pubmed-meshheading:17582943-Hematopoietic Stem Cells,
pubmed-meshheading:17582943-Humans,
pubmed-meshheading:17582943-Leukapheresis,
pubmed-meshheading:17582943-Lymphoma, Non-Hodgkin,
pubmed-meshheading:17582943-Male,
pubmed-meshheading:17582943-Methotrexate,
pubmed-meshheading:17582943-Middle Aged,
pubmed-meshheading:17582943-Prednisone,
pubmed-meshheading:17582943-Retrospective Studies,
pubmed-meshheading:17582943-Vincristine
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
The use of G-CSF during first line chemotherapy adversely affects the yield of PBSC mobilization in non-Hodgkin's lymphoma patients.
|
|
pubmed:affiliation |
Chair and Division of Hematology, Bone Marrow Transplant Unit, Department of Medical and Morphological Research, University Hospital, Udine, Italy. Daniela.Damiani@DRMM.uniud.it
|
|
pubmed:publicationType |
Journal Article
|
